Loading...
Docoh

Xeris Pharmaceuticals (XERS)

Utility
Precipitation Resistant Small Molecule Drug Formulations
31 Mar 22
Embodiments of the invention are directed to formulations that provide a solution to the problem of small molecule (e.g., diazepam) precipitation at the injection site when administered as a highly-concentrated formulation.
Steven J. PRESTRELSKI, Michael A. SANDOVAL, Brian R. SLOAT
Filed: 13 May 21
Utility
Stable Sustained Release Therapeutic Compositions In Aprotic Polar Solvents and Methods of Manufacturing the Same
30 Dec 21
The present invention relates to the use of aprotic polar solvents and an ionization stabilizing agent to prepare storage stable sustained release therapeutic formulations by dissolving a therapeutic agent (active ingredient) in an aprotic polar solvent system that can then be administered to patients suffering from or predisposed to a variety of physical conditions or disorders, notably hypoglycemia.
Evan CASSAVAUGH, Steven PRESTRELSKI
Filed: 25 Jun 21
Utility
Stable Formulations for Parenteral Injection of Peptide Drugs
14 Oct 21
Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided.
Steven PRESTRELSKI, John KINZELL
Filed: 29 Mar 21
Utility
Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
28 Sep 21
This disclosure includes syringes, kits containing the same, and related methods.
Martin Donovan
Filed: 6 Aug 15
Utility
Precipitation resistant small molecule drug formulations
1 Jun 21
Embodiments of the invention are directed to formulations that provide a solution to the problem of small molecule (e.g., diazepam) precipitation at the injection site when administered as a highly-concentrated formulation.
Steven J. Prestrelski, Michael A. Sandoval, Brian R. Sloat
Filed: 31 May 18
Utility
Stable formulations for parenteral injection of peptide drugs
27 Apr 21
Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided.
Steven Prestrelski, John Kinzell
Filed: 22 Mar 16
Utility
Treatment of Post-bariatric Hypoglycemia Using Mini-dose Stable Glucagon
4 Feb 21
Post-bariatric hypoglycemia (PBH) is an increasingly-recognized complication of gastric bypass surgery.
Brett NEWSWANGER, Steven J. PRESTRELSKI, Mary-Elizabeth PATTI
Filed: 23 Jan 19
Utility
Treatment of Exercise-induced Hypoglycemia In Type 1 and Insulin Using Type 2 Diabetes
14 Jan 21
Certain embodiments are directed to methods for treating, ameliorating, or preventing exercise-induced or exercise-associated hypoglycemia comprising administration to a subject in need thereof a formulation(s) of glucagon or glucagon analog in an amount effective to treat, ameliorate, or prevent the condition.
Steven PRESTRELSKI, Brett NEWSWANGER, Martin CUMMINS, Michael RIDDELL
Filed: 21 Dec 18
Utility
Stable Therapeutic Compositions In Aprotic Polar Solvents and Methods of Manufacturing the Same
2 Dec 20
The present invention concerns the use of aprotic polar solvents, water, and an ionization stabilizing agent to prepare device compatible stable therapeutic formulations by dissolving a therapeutic agent (active ingredient) in an aprotic polar solvent system that can then be used with various devices (e.g., pumps, infusion sets) for administration of the formulation.
Martin DONOVAN, Wendy HU
Filed: 28 May 20
Utility
Stable Formulations for Parenteral Injection of Small Molecule Drugs
25 Nov 20
Disclosed is a stable liquid formulation for parenteral injection comprising a biocompatible non-aqueous solvent and a small molecule drug, or a salt thereof, solubilized within the non-aqueous solvent, wherein the liquid formulation comprises less than 10% by weight residual water, and wherein the volume of the liquid formulation to be parenterally injected is from 0.1 μl to 3 ml.
Steven J. PRESTRELSKI, Nancy SCOTT
Filed: 30 Jul 20
Utility
Stable formulations for parenteral injection of small molecule drugs
7 Sep 20
Disclosed is a stable liquid formulation for parenteral injection comprising a biocompatible non-aqueous solvent and a small molecule drug, or a salt thereof, solubilized within the non-aqueous solvent, wherein the liquid formulation comprises less than 10% by weight residual water, and wherein the volume of the liquid formulation to be parenterally injected is from 0.1 μl to 3 ml.
Steven J. Prestrelski, Nancy Scott
Filed: 28 Jul 15
Utility
Methods for Producing Stable Therapeutic Formulations in Aprotic Polar Solvents
8 Jul 20
Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.
Steven Prestrelski, Michael Sandoval, Martin Donovan
Filed: 13 Oct 19
Utility
Methods for Treating Congenital Hyperinsulinism
13 May 20
A method of treating congenital hyperinsulinism in a subject is disclosed.
STEVEN PRESTRELSKI, JOHN KINZELL, BRETT NEWSWANGER, PAUL THORNTON, POUL STRANGE, MARTY CUMMINS
Filed: 13 Jul 18
Utility
Methods for producing stable therapeutic formulations in aprotic polar solvents
25 Nov 19
Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.
Steven Prestrelski, Michael Sandoval, Martin Donovan
Filed: 14 May 17
  • 1
Patents are sorted by USPTO publication date, most recent first